Dr Sree Rodda
MBBS, MRCR and FRCR
Languages spoken
English
Expert in
Prostate, Bladder and Kidney Cancers
Overview
Dr Sree Lakshmi Rodda is a Consultant Clinical Oncologist at Leeds Teaching Hospitals NHS Trust, specialising in the treatment of prostate, bladder, and kidney (renal) cancers. Since her appointment as a consultant in 2016, she has dedicated her practice to caring for patients with urological cancers, providing expert diagnosis, personalised treatment planning, advanced radiotherapy, and specialist second opinions.
Dr Rodda completed her specialist Clinical Oncology training within the Yorkshire Deanery before undertaking an advanced fellowship in prostate brachytherapy at the internationally renowned BC Cancer Agency in Vancouver, Canada. During her fellowship, she developed advanced expertise in prostate brachytherapy, treating patients with localised and advanced prostate cancer using the latest radiotherapy techniques.
She is recognised for her expertise in prostate brachytherapy, MRI-guided radiotherapy, stereotactic radiotherapy (SABR/SBRT), and precision cancer treatment. Dr Rodda has published extensively in peer-reviewed medical journals, particularly in the field of prostate brachytherapy, reflecting her commitment to advancing cancer treatment and improving outcomes for patients with urological cancers.
Dr Rodda cares for patients with newly diagnosed, recurrent, and advanced prostate, bladder, and kidney cancers. She works closely with multidisciplinary teams to develop personalised treatment plans based on the latest clinical evidence and each patient's individual needs and priorities.
Her expertise includes external beam radiotherapy (EBRT), MRI-guided adaptive radiotherapy (MR Linac), MRI-guided stereotactic ablative radiotherapy (MRI-guided SABR), stereotactic body radiotherapy (SBRT/SABR), renal SABR, volumetric modulated arc therapy (VMAT), image-guided radiotherapy (IGRT), high-dose-rate (HDR) and low-dose-rate (LDR) prostate brachytherapy, chemotherapy, androgen deprivation therapy (ADT), and personalised systemic cancer treatments.
Patients value Dr Rodda for her calm, approachable, and compassionate manner. She believes that every patient deserves the time to understand their diagnosis, ask questions, and feel confident in their treatment decisions. By combining advanced technology with clear communication and personalised care, she aims to achieve the best possible outcomes while supporting patients and their families throughout every stage of their cancer journey.
Career positions
Current position(s)
- Consultant Clinical Oncologist, GenesisCare Leeds, Nottingham, Oxford and Cromwell.
- Consultant Clinical Oncologist, NOVA Healthcare Leeds.
- Consultant Clinical Oncologist, Leeds Teaching Hospital.
Expertise and interests
- Prostate brachytherapy
Professional memberships
- Fellow of the Royal College of Radiologists
Awards
Nominated for the Kate Granger Award for Compassionate Care at Mid Yorkshire Hospitals
Publications and Affiliations
1. Parker CC, et al. RADICALS investigators. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet. 2024;403(10442):2416–2425. doi: 10.1016/S0140-6736(24)00549-X
2. Clark AK, et al. Single- and dual-source-strength focal boost planning in low-dose-rate prostate brachytherapy: feasibility study. Journal of Radiotherapy in Practice. 2023;22:e106. doi:10.1017/S1460396923000225
3. Slevin F, et al. A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy. Clinical and Translational Radiation Oncology. 2019;20:1–8. doi: 10.1016/j.ctro.2019.10.001
4. Rodda S, et al. ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology - Biology - Physics. 2017;98(3):581–589. doi: 10.1016/j.ijrobp.2017.02.027
5. Henry AM, et al. The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy. Clinical Oncology. 2015;27(7):382–386. doi: 10.1016/j.clon.2015.03.004
